Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
In July 2018, Fujifilm Manufacturing Europe announced plans to construct a facility to manufacture cell culture media in Tilburg, the Netherlands.
The facility will allow the company to better meet its customers’ requirements, particularly in Europe. It will be the company’s third manufacturing site, joining two existing facilities in California, US, and Tokyo, Japan.
The existing manufacturing sites are compliant with the International Standardisation Organisation (ISO) and the US Food and Drug Administration (FDA) regulations.
Construction of the facility is currently underway, with completion scheduled for the second half of 2021. The facility will create between 50 and 70 jobs.
Fujifilm’s manufacturing facility location
Fujifilm’s facility will be located in the southern province of Brabant in Tilburg.
Brabant was chosen as the preferred location due to its open innovation, active collaboration, as well as research and development (R&D) infrastructure, sustainability features and highly talented workforce.
Details of Fujifilm’s manufacturing facility
Fujifilm Manufacturing Europe is transforming Fujifilm’s existing factory in Tilburg into a current good manufacturing practice (cGMP) compliant cell culture media production facility that will have a floor area of 250,000ft².
The facility will be used to produce dry powder and liquid media, as well as downstream bioprocessing liquids.
The move will increase the company’s annual dry powder production capacity by approximately 320,000kg.
A liquid media production capacity of 470,000l a year will be added to the facility, which will support the manufacturing of water for injection (WFI).
Cell culture media provides the nutrition required for cell growth. It is an raw material used for the development and commercialisation of various biologics and cell therapies.
Cell culture media production is a complicated process and requires high technical expertise and precision engineering.
Fujifilm uses ISO: 13485:2016-certified quality system, control on raw materials and high technical skills to supply an extensive portfolio of cell culture media solutions.
The cell culture media solutions include Ham’s F-10 and F-12 media, alongside Dulbecco’s Modified Eagle’s Medium (DMEM), which is the modified version of Basal Medium Eagle (BME).
The solutions include McCoy’s Medium 5A and Click’s medium, which contain a higher concentration of vitamins, minerals and amino acids for primary and established cell lines.
Other cell culture media are RPMI 1640 to culture human leukaemia and hybridoma cells and synthetic cell culture media such as minimum essential medium (MEM) and alpha-MEM.
The company offers WFI, which is the sterile, clear, and colourless liquid suitable to produce cell culture media and rinse water and to reconstitute biochemical reagents.
Marketing commentary on Fujifilm
Fujifilm is an imaging company based in Japan, whereas Fujifilm Manufacturing Europe is one of the company’s biggest production centres of photographic materials outside Japan.
The production processes in the facility have been powered by wind energy since 2016. The company employs approximately 900 people at its three production facilities.
Fujifilm strategically acquired two cell culture media companies, Irvine Scientific and IS Japan, in June 2018 to grow its healthcare segment.
Fujifilm Irvine Scientific provides services and products to biopharmaceuticals, regenerative medicine, cell therapy, and assisted reproductive technology industry for the large-scale production of therapeutics and vaccines.
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…
Bushu Pharmaceuticals unveiled a new expansion programme for its pharmaceutical manufacturing facility in Misato, Japan, in August 2020. With the…